Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis

Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis

Background: New, complex, and expensive therapies targeting Interleukin-5 (IL-5) to treat severe eosinophilic asthma are emerging. Objective: To assess efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab for treating severe eosinophilic asthma. Design: A systematic revi...

Full description

Bibliographic Details
Main Authors: Daniel P. Henriksen, Uffe Bodtger, Kirsten Sidenius, Niels Maltbaek, Lars Pedersen, Hanne Madsen, Ehm A. Andersson, Ole Norgaard, Louise Klokker Madsen, Bo L. Chawes
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:European Clinical Respiratory Journal
Subjects:
Severe asthma
anti-IL-5
reslizumab
mepolizumab
systematic review
Online Access:http://dx.doi.org/10.1080/20018525.2018.1536097

Internet

http://dx.doi.org/10.1080/20018525.2018.1536097

Similar Items